Detalhe da pesquisa
1.
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases.
Br J Cancer
; 128(7): 1286-1293, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36717671
2.
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Oncologist
; 28(9): e703-e711, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36940301
3.
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Oncologist
; 25(9): e1355-e1362, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32618068
4.
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study.
Breast J
; 26(7): 1296-1301, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31837103
5.
Escalation and de-escalation in HER2 positive early breast cancer.
Curr Opin Oncol
; 31(1): 35-42, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30325338
6.
Immune characterization of breast cancer metastases: prognostic implications.
Breast Cancer Res
; 20(1): 62, 2018 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29929548
7.
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer.
Clin Cancer Res
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38656833
8.
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.
Cancer Treat Rev
; 102: 102323, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34896969
9.
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?
Cancer Treat Rev
; 110: 102462, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087503
10.
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.
NPJ Breast Cancer
; 8(1): 66, 2022 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35595761
11.
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.
Clin Cancer Res
; 28(2): 308-317, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34667023
12.
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review.
Case Rep Oncol
; 14(1): 160-164, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33776698
13.
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.
Front Oncol
; 11: 625636, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33777770
14.
Evolution of HER2-low expression from primary to recurrent breast cancer.
NPJ Breast Cancer
; 7(1): 137, 2021 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34642348
15.
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy.
NPJ Breast Cancer
; 7(1): 101, 2021 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341356
16.
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center.
J Womens Health (Larchmt)
; 28(4): 544-550, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29963941
17.
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease.
Front Oncol
; 9: 452, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31245286
18.
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer.
NPJ Breast Cancer
; 7(1): 149, 2021 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819500
19.
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis.
Breast
; 47: 77-84, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31357134